Joao A Lima
Overview
Explore the profile of Joao A Lima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellissimo M, Carbone S, He J, Jordan J, Ambale-Venkatesh B, Lima J, et al.
Prog Cardiovasc Dis
. 2023 Oct;
81:10-16.
PMID: 37852519
Background: Cancer therapies induce cardiac injury and increase cardiovascular disease (CVD) risk. In non-cancer populations, higher diet quality is associated with protection against CVD, but the relationship between diet and...
2.
Ilkhanoff L, Qian X, Lima J, Tran H, Soliman E, Yeboah J, et al.
Am J Cardiol
. 2023 Aug;
204:287-294.
PMID: 37567020
Abnormalities in myocardial substrate, including diffuse and replacement fibrosis, increase the risk of cardiovascular disease (CVD). Data are sparse on whether electrocardiogram (ECG) measures, coupled with circulating biomarkers, may aid...
3.
deFilippi C, Tran H, Gattani R, Daniels L, Shah P, Ilkhanoff L, et al.
Front Cardiovasc Med
. 2023 Feb;
10:1104715.
PMID: 36844723
Background: Subclinical abnormalities in myocardial structure (stage B heart failure) may be identified by cardiac and non-organ specific biomarkers. The associations of high-sensitivity cardiac troponin T (hs-cTnT) and growth differentiation...
4.
Zhang X, Angelini E, Haghpanah F, Laine A, Sun Y, Hiura G, et al.
Magn Reson Imaging
. 2022 Jul;
92:140-149.
PMID: 35777684
Purpose: To develop an end-to-end deep learning (DL) framework to segment ventilation defects on pulmonary hyperpolarized MRI. Materials And Methods: The Multi-Ethnic Study of Atherosclerosis Chronic Obstructive Pulmonary Disease (COPD)...
5.
Appiah D, Nwabuo C, Ebong I, Vasconcellos H, Wellons M, Lewis C, et al.
Menopause
. 2022 Mar;
29(5):564-572.
PMID: 35324538
Objective: The association between menopause and incident cardiovascular disease (CVD) is controversial. We evaluated the relationships of estrogen deficiency (ovarian reproductive aging) assessed by age at natural menopause (ANM), chronological...
6.
Berardi C, Bluemke D, Houston B, Kolb T, Lima J, Pezel T, et al.
J Heart Lung Transplant
. 2022 Feb;
41(5):619-625.
PMID: 35184966
Background: Soluble Fms-like tyrosine kinase 1 (sFlt-1) may inhibit angiogenesis. Higher levels of sFlt-1 are associated with worse prognosis in prevalent heart failure patients. The aim of this study was...
7.
Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J, et al.
Eur J Heart Fail
. 2021 Apr;
23(4):661-674.
PMID: 33811444
Aims: CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given...
8.
Subramanya V, Zhao D, Ouyang P, Ying W, Vaidya D, Ndumele C, et al.
Biomarkers
. 2021 Mar;
26(4):309-317.
PMID: 33715578
Cyclic guanosine monophosphate (cGMP) is a second messenger for natriuretic peptide (NP) and nitric oxide pathways; its enhancement a target for heart failure and cardiovascular disease (CVD). We evaluated whether...
9.
Bolli R, Perin E, Willerson J, Yang P, Traverse J, Henry T, et al.
JACC CardioOncol
. 2021 Jan;
2(4):581-595.
PMID: 33403362
Background: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach...
10.
Zhao D, Guallar E, Vaidya D, Ndumele C, Ouyang P, Post W, et al.
J Am Heart Assoc
. 2020 Jan;
9(2):e013966.
PMID: 31928156
Background Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with...